Lively Debate at HIPAA Summit at Harvard


By Neil Versel

August 19, 2008 | CAMBRIDGE, Mass.—Are patient privacy rules effective? The answer is not a simple yes or no.

“It’s working, but it’s got a ways to go,” suggests William Braithwaite, chief medical officer of San Diego-based security and identity management company Anakam. He says that current federal and state privacy rules generally do not address new technologies such as mobile Internet access and personal health records (PHR) platforms.

Deborah Peel, founder and chair of Patient Privacy Rights and the affiliated Coalition for Patient Privacy, begs to differ. She says the August 2002 amendments to the original HIPAA privacy rule effectively eliminated the patient’s right to consent to the use of protected health information by adding permission to share such data for “treatment, payment, and health care operations.”

Braithwaite, known as “Doctor HIPAA” because he helped draft the rules last decade when he was a senior advisor on health-IT policy in the Department of Health and Human Services (HHS), and Peel were part of a lively roundtable discussion and debate Tuesday morning at the Sixteenth National HIPAA Summit and related Privacy Symposium on the Harvard University campus.

Joining them on the panel were Karen Grant, chief privacy officer at Partners Healthcare System in Boston, and Linda Sanches, senior advisor for HIPAA privacy outreach and training in the HHS Office for Civil Rights. Jodi Daniel, director of the Office of Policy and Research in the Office of the National Coordinator for Health Information Technology, participated via telephone.

Peel believes a stronger privacy law that requires patient consent could promote data exchange between health care entities that currently are wary of sharing information with competitors. “The consent tool can really enable regional data exchange,” says Peel, an Austin, Texas, psychiatrist.

“The person who can really move the data safely is in the consumer,” according to Peel. “We can be pinged on our cell phones if someone we don’t know wants access to our data.

Sanches says health care professionals and the public alike may mistakenly believe HIPAA enforcement has been lax because HHS has imposed few monetary penalties. “We see enforcement as the improvement of privacy activities among covered entities,” she says.

“That normally requires them to take drastic action,” Sanches says. She notes that people have been disciplined for taking unauthorized looks at the medical records of celebrities, such as the more than two dozen employees at Palisades Medical Center in New Jersey were suspended last year for peeking at the records of actor George Clooney.

But Peel says that health care organizations generally only take action when there is a high-profile breach such as with Clooney because electronic health records (EHRs) systems are set up to follow the HIPAA requirement that there be an audit trail of who viewed protected health information and when. EHRs, she argues, generally do not take proactive steps to prevent unauthorized access to specific records by people who have network passwords.

In fact, according to Peel, EHR vendors, which often are not covered entities under HIPAA, routinely aggregate and sell patient data without patient consent. “It is cheaper to have a consent-management tool than to search retroactively for needles in a haystack,” Peel says.

Braithwaite says it is unfair to blame vendors as a bunch because products and security protocols vary greatly. “You can’t make a blanket statement like that. It’s ridiculous,” he contends.

And so the debate continues.

 

 

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

Waters white paper image
Software Helps Doping Control Lab Streamline Results Management
Sponsored by Waters
The Karolinska University Hospital’s Doping Control Lab tests thousands of samples annually for stimulants, diuretics, and other masking agents. Increased regulatory pressure and new technologies increased the number of samples analyzed creating data management challenges. Waters® NuGenesis® Scientific Data Management System and TargetLynx™ Application Manager software were used to reduce the time required to calculate, review and search results.


sas whitepaper92
Managed Innovation, Assured Compliance
Sponsored by SAS
Discovery organizations are identifying a lot of promising compounds, but clinical research processes haven't kept pace with timely testing of all those potential therapies. This white paper describes how SAS® Drug Development supports true innovation across the clinical trial process.

In this white paper you will learn how to:

  • Assemble data to foster better collaboration
  • Get up-to-date information during clinical trials
  • Make informed decisions earlier in the trial process


BlueArc white paper image
Addressing Life Sciences Constantly Growing Data Challenges Research Environments
Sponsored by BlueArc
The continued explosion of raw experimental data, the increased use of video, the growing adoption of new data retention practices, and the move to high throughput computational workflows are all placing new demands on the way life sciences organizations store and manage their data.

Download this white paper to learn about:

  • Factors driving the data explosion in the life sciences
  • New data management issues that must be addressed
  • HPC trends that are placing new demands on storage
  • Storage solution attributes that address performance, manageability, and energy efficiency.


Life Science Webcasts & Podcasts

Medidata Solutions

Rising Clinical Trial Delays and Costs - Addressing the Cause, Not the Symptoms 

medidata podcastProtocol complexity is taking a toll on clinical study speed and efficiency: increasingly complicated and ambitious protocols are not only burdening sites and study volunteers but are also prolonging trials and increasing expenses. In response, sponsors have turned to global study placement, restructured site relationships and new site management practices, but the problem remains.

This podcast will discuss:

  • Why these responses address only the symptoms, not the underlying cause, of rising clinical trial delays and costs.
  • Results of a recent joint Tufts University / Medidata Solutions study.
  • New metrics benchmarking protocol design trends.
  • Systematic protocol design improvements and why they are essential to clinical trial performance excellence.

Speakers: Ken Getz, Senior Research Fellow at the Tufts Center for the Study of Drug Development, and Ed Seguine, General Manager, Trial Planning Solutions at Medidata.

Download Now 



More Podcasts

Job Openings

Director, Center For Information Technology (CIT) - National Institutes of Health  (NIH), Department of Health and Human Service
Located in Bethesda, MD. This position requires:
• High-level vision, leadership, management, and modernization of CIT programs and services.
• Strategic direction and policy development for CIT long-term operations and objectives.
• Serve as a key IT advisor to the NIH Chief Information Officer.
A TOP SECRET security clearance will be required.  More job detail is found at:  http://www.jobs.nih.gov under the Executive Jobs section.Or contact Ms.Winnie Garner at seniorre@od.nih.gov.  Applications must be received ELECTRONICALLY by (11:59 p.m.), December 17, 2008.  DHHS and NIH are Equal Opportunity Employers

Bioinformatics Manager- Lilly Singapore Centre for Drug Discovery
For more information click here 

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.